Opinion

Video

Efficacy and Safety of Subcutaneous Infliximab

A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile.

  1. What are the key findings regarding the clinical remission and endoscopic response of subcutaneous infliximab-dyyb injection from the LIBERTY CD and LIBERTY UC trials?
  2. How does subcutaneous infliximab injection compare to IV infliximab in terms of sustenance of drug levels?
    • Are there any clinical advantages of the subcutaneous delivery over the IV route?
  3. How does the safety profile of subcutaneous infliximab injection compare to IV infliximab?
Related Videos
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
4 experts are featured in this series.
4 experts are featured in this series.
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.